bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-71-5010-01

Order Name:
HLA-B 1502 - Please use order Pharmacogenomics in HLA-B **

 
Useful For:
Genotyping for HLA-B*15:02 before carbamazepine therapy
 
Methodology:
Polymerase chain reaction
 
AliasesName:
Pharmacogenetic for HLA-B15:02
Carbamazepine Hypersensitivity
Oxcarbazepine Hypersensitivity
Phenytoin Hypersensitivity
HLAB1502
HLA B*15:02
 
 
 
Test Code:
090-71-5010-01

Order Name:
HLA-B 1502 - Please use order Pharmacogenomics in HLA-B **

 
Collection Specimen Or Container:
Blood/ K3 EDTA (Lavender Top) 3 mL, 2 tubes
 
Specimen Testing Type:
Whole Blood EDTA, minimum volume 3 mL
 
Sub Mission Container:
Original tube
 
Rejection Criteria:
Hemolysis: Hemolysis interfere
Other: Over Stability will be reject
 
Specimen Stabillity:
Specimen Type Temperature Time
Whole blood, EDTA Ambient (preferred) Same day
Refrigerated, 2oC to 8oC 7 days
 
 
 
Test Code:
090-71-5010-01

Order Name:
HLA-B 1502 - Please use order Pharmacogenomics in HLA-B **

 
Method detail:
Polymerase chain reaction
 
Schedule:
N/A **Sent Out to Ramathibodi
 
Turnaround Time:
Reported within 3-5 days (exception for official holidays)
 
Performing Location:
Ramathibodi
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-71-5010-01

Order Name:
HLA-B 1502 - Please use order Pharmacogenomics in HLA-B **

 
 
Clinical Information:
Carbamazepine is an aromatic anticonvulsant. Oxcarbamazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital are also in this category. Carbamazepine is FDA-approved for the treatment of epilepsy, trigeminal neuralgia, and bipolar disorder. According to the most recent Clinical Pharmacogenetic Implementation Consortium (CPIC) guideline, patients who are HLA-B*15:02 positive should not be prescribed carbamazepine or oxcarbamazepine if alternative agents are available; however, caution should be used in selecting an alternative medication as there is weaker evidence that also links other aromatic anticonvulsants with SJS/TEN in patients positive for HLA-B*15:02. Furthermore, phenytoin is the subject of a separate CPIC guideline with recommendations to avoid phenytoin in HLA-B*15:02 positive.
 
Reference Value:
Negative
 
Interpretation:
The presence of the HLA-B*15:02 allele confers increased risk for hypersensitivity to carbamazepine, oxcarbazepine and phenytoin. Cautions: HLA-A*31:01 allele also confers increased risk for hypersensitivity to carbamazepine.
 
Clinical Reference:
  1. www.si.mahidol.ac.th (Retrieved: 18 Jan 2019)
  2. www.mayomedicallaboratories.com (Retrieved: 18 Jan 2019)